Kestra Advisory Services LLC trimmed its position in shares of Sanofi (NASDAQ:SNY – Free Report) by 56.4% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 60,459 shares of the company’s stock after selling 78,280 shares during the quarter. Kestra Advisory Services LLC’s holdings in Sanofi were worth $2,493,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors and hedge funds have also recently modified their holdings of the company. Allworth Financial LP grew its holdings in shares of Sanofi by 2.7% in the second quarter. Allworth Financial LP now owns 9,233 shares of the company’s stock worth $394,000 after acquiring an additional 243 shares during the period. Focused Alpha LLC increased its position in Sanofi by 4.5% during the third quarter. Focused Alpha LLC now owns 6,553 shares of the company’s stock valued at $270,000 after acquiring an additional 281 shares during the last quarter. Intrua Financial LLC increased its position in Sanofi by 6.4% during the third quarter. Intrua Financial LLC now owns 5,100 shares of the company’s stock valued at $210,000 after acquiring an additional 309 shares during the last quarter. Arkadios Wealth Advisors increased its position in Sanofi by 0.9% during the first quarter. Arkadios Wealth Advisors now owns 36,146 shares of the company’s stock valued at $1,742,000 after acquiring an additional 315 shares during the last quarter. Finally, Avior Wealth Management LLC lifted its holdings in Sanofi by 5.2% in the third quarter. Avior Wealth Management LLC now owns 6,412 shares of the company’s stock valued at $264,000 after acquiring an additional 319 shares during the period. 14.03% of the stock is currently owned by hedge funds and other institutional investors.
Sanofi Stock Performance
Shares of SNY stock opened at $48.37 on Monday. Sanofi has a 1 year low of $39.07 and a 1 year high of $52.67. The firm has a fifty day moving average price of $42.68 and a 200-day moving average price of $44.38. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.12 and a quick ratio of 0.27. The company has a market cap of $117.27 billion, a price-to-earnings ratio of 23.95, a PEG ratio of 1.32 and a beta of 0.31.
Sanofi (NASDAQ:SNY – Get Free Report) last posted its quarterly earnings data on Friday, October 30th. The company reported $2.04 EPS for the quarter, topping the consensus estimate of $1.56 by $0.48. Sanofi had a return on equity of 15.16% and a net margin of 8.70%. The firm had revenue of $17.25 billion during the quarter, compared to analyst estimates of $14.30 billion. During the same period in the prior year, the business posted $2.91 EPS. Sanofi’s revenue was up 16.2% on a year-over-year basis. As a group, equities analysts predict that Sanofi will post 5.07 earnings per share for the current year.
Analyst Ratings Changes
Several research analysts have issued reports on the company. Deutsche Bank reissued a “buy” rating on shares of Sanofi in a research report on Tuesday, September 29th. Sanford C. Bernstein reaffirmed a “buy” rating on shares of Sanofi in a research report on Monday, August 3rd. Berenberg Bank reaffirmed a “buy” rating on shares of Sanofi in a research report on Monday, October 5th. Royal Bank Of Canada started coverage on shares of Sanofi in a research note on Tuesday, September 8th. They issued a “sector perform” rating on the stock. Finally, Jefferies Financial Group reissued a “buy” rating on shares of Sanofi in a report on Thursday, October 1st. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and twelve have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $53.00.
View Our Latest Stock Analysis on SNY
Sanofi Profile
Sanofi is a France-based global biopharmaceutical company that researches, develops, manufactures and markets medicines and vaccines. Its work spans areas including immunology, oncology, rare diseases and neurology, as well as preventive vaccines. The company’s portfolio includes Dupixent, an immunology medicine developed with Regeneron, and vaccines for diseases such as influenza and meningitis. Sanofi serves patients and healthcare providers in markets around the world. Sanofi traces its origins to a company established in France in 1973.
Further Reading
- Five stocks we like better than Sanofi
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.
